Nohla Therapeutics

Nohla is the leading developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases.

[Nohla Therapeutics @nohlatx]

It was an honor to celebrate #wcbd18 with cord blood transplant recipients who serve as a constant reminder of #WhyWeAreHere. #dilanubicel #nohla

[Nohla Therapeutics @nohlatx]

Getting ready to host some special guests at Nohla on World Cord Blood Day. #WCBD18

[Nohla Therapeutics @nohlatx]

Nohla is hiring! Positions include clinical data and trial managers, medical writer, regulatory affairs, QC, exec assistant/officer manager, analytical development, manufacturing & project management. https://t.co/vrspyHtEsR

[Nohla Therapeutics @nohlatx]

Nohla announces FDA Fast Track designation for dilanubicel for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. https://t.co/phGgmiWdvF #fasttrack #dilanubicel

[Nohla Therapeutics @nohlatx]

FDA has granted @nohlatx ’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). https://t.co/G6GDe0CWpD #stemcells

[Nohla Therapeutics @nohlatx]

@NohlaTx today announced the second closing of its Series B financing, bringing the total amount raised in this round to $56 million. https://t.co/gOTV1B8ouc

[Nohla Therapeutics @nohlatx]

Congrats to our founder, Colleen Delaney, who was awarded the 2018 Seattle AWIS award last night. https://t.co/WVM3vEsB6R

[Seattle AWIS @SeattleAWIS]

Congrats to Colleen Delaney of @nohlatx and @fredhutch for receiving the 2018 Seattle AWIS award for Scientific Advancement and Leadership in STEM.

[Nohla Therapeutics @nohlatx]

Nohla announces presentation of dilanubicel (NLA101) data at EHA Annual Meeting showcasing compelling evidence of rapid immune recovery and improved long-term outcomes after hematopoietic stem cell transplant. #dilanubicel #nohlatx https://t.co/IXPqHQoQJC

[Nohla Therapeutics @nohlatx]

Nohla receives EMA PRIME designation for Dilanubicel for HSCT patients. First product to achieve PRIME Designation for HSCT. Since its inception in 2016, only 21% of PRIME requests have been granted by the EMA. #nohlatx #EMAPRIME #dilanubicel https://t.co/bGSSuHDf3y

[Nohla Therapeutics @nohlatx]

Nohla featured in WSJ, “Promise for Bone-Marrow Transplants,” and how it’s developing a differentiated treatment approach for patients undergoing an allogeneic cord blood transplant. #nohlatx #offtheshelf #celltherapy https://t.co/v4Whb5I6V4

[Nohla Therapeutics @nohlatx]

Nohla announces EHA abstract acceptance on dilanubicel showing excellent long-term survival outcomes - 86% Disease-Free and Overall Survival rates in patients 5 years after cord blood transplantation. Nohla’s abstract is now available online https://t.co/0MlNgh6MxE

[Nohla Therapeutics @nohlatx]

@ldtimmerman @climbtofight @fredhutch Good luck to you. All of us @nohlatx are cheering all the way from Seattle.

[Nohla Therapeutics @nohlatx]

Nohla announces closing of a $45 million Series B financing. New investors, Fidelity and Celgene, joined existing investors, ARCH Venture Partners, 5AM, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing https://t.co/sZsQ1R8r1z

[Nohla Therapeutics @nohlatx]

Nohla has appointed industry veteran, Gary Christianson, as its new COO. His commercial and operational expertise is a welcome addition to the Nohla leadership team. https://t.co/6u2aCsFjBq

[Nohla Therapeutics @nohlatx]

Nohla is hiring -- check out our current openings in clinical, finance, manufacturing, process development and project management. https://t.co/vrspyHtEsR

[Nohla Therapeutics @nohlatx]

Today's news can be found at https://t.co/Qw1L2qJeRb

[Nohla Therapeutics @nohlatx]

Nohla and @adv_therapies announced today we’ve entered into a commercial agreement for the production of Nohla's NLA101, our universal donor, off the shelf cell therapy product. The agreement will support ongoing development and anticipated global commercial demand. #celltherapy

[Luke Timmerman @ldtimmerman]

I'm Climbing Mt. Everest to Support Cancer Research @fredhutch Watch VIDEO-> https://t.co/DVZldsUpkw DONATE HERE-> https://t.co/QCxnCjGKNr

[Nohla Therapeutics @nohlatx]

Nohla Therapeutics Initiates Global LAUNCH Phase 2 Trial of NLA101 in Patients with AML https://t.co/5uhUBkrIxA

[Nohla Therapeutics @nohlatx]

Nohla annnounced today that the European Commission has granted Orphan Drug Designation to NLA101 as an orphan medicinal product for the treatment in hematopoietic stem cell transplantation. https://t.co/th66A0vfmX